Literature DB >> 20176907

Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus.

Christopher S Lunde1, Charles H Rexer, Stephanie R Hartouni, Sabine Axt, Bret M Benton.   

Abstract

The cellular binding patterns of fluorescent conjugates of telavancin and vancomycin were evaluated in Staphylococcus aureus by fluorescence microscopy and ratio imaging analysis. Telavancin showed enhanced binding at the division septum compared to vancomycin. This result is consistent with observations that telavancin binds with higher affinity to lipid II than to d-Ala-d-Ala residues in the cell wall, thus demonstrating the preferential binding of telavancin to the site of active cell wall biosynthesis.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20176907      PMCID： PMC2863671          DOI： 10.1128/AAC.01609-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  Bacterial cell wall synthesis: new insights from localization studies.

Authors:  Dirk-Jan Scheffers; Mariana G Pinho
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

3.  Imaging peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics.

Authors:  Kittichoat Tiyanont; Thierry Doan; Michael B Lazarus; Xiao Fang; David Z Rudner; Suzanne Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

4.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

5.  Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.

Authors:  Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2006-06-20       Impact factor: 5.790

6.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms.

Authors:  Kimberly K Jefferson; Donald A Goldmann; Gerald B Pier
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Authors:  Christopher S Lunde; Stephanie R Hartouni; James W Janc; Mathai Mammen; Patrick P Humphrey; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

9.  Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery.

Authors:  Mariana G Pinho; Jeff Errington
Journal:  Mol Microbiol       Date:  2003-11       Impact factor: 3.501

10.  Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates.

Authors:  Mariana G Pinho; Jeff Errington
Journal:  Mol Microbiol       Date:  2005-02       Impact factor: 3.501
View more
  13 in total

1.  Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors:  Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  Glutamine synthetase and glucose-6-phosphate isomerase are adhesive moonlighting proteins of Lactobacillus crispatus released by epithelial cathelicidin LL-37.

Authors:  Veera Kainulainen; Vuokko Loimaranta; Anna Pekkala; Sanna Edelman; Jenni Antikainen; Riikka Kylväjä; Maiju Laaksonen; Liisa Laakkonen; Jukka Finne; Timo K Korhonen
Journal:  J Bacteriol       Date:  2012-03-02       Impact factor: 3.490

4.  Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly E Steed; Céline Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Jessica Hallesy; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

6.  Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies.

Authors:  Yang Song; Christopher S Lunde; Bret M Benton; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

7.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

Review 8.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

9.  Antibiofilm and membrane-damaging potential of cuprous oxide nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Avinash Singh; Asar Ahmed; Kashi N Prasad; Sonali Khanduja; Satyendra K Singh; Janmejai K Srivastava; Namdeo S Gajbhiye
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

10.  Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm.

Authors:  Ken-ichi Okuda; Takeshi Zendo; Shinya Sugimoto; Tadayuki Iwase; Akiko Tajima; Satomi Yamada; Kenji Sonomoto; Yoshimitsu Mizunoe
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.